Equinix Inc (EQIX)vsNovo Nordisk A/S (NVO)
EQIX
Equinix Inc
$1,082.83
-0.57%
REAL ESTATE · Cap: $106.79B
NVO
Novo Nordisk A/S
$42.22
+4.79%
HEALTHCARE · Cap: $187.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 3238% more annual revenue ($309.06B vs $9.26B). NVO leads profitability with a 33.1% profit margin vs 14.6%. NVO appears more attractively valued with a PEG of 4.42. NVO earns a higher WallStSmart Score of 55/100 (C).
EQIX
Buy50
out of 100
Grade: C-
NVO
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.5%
Fair Value
$626.41
Current Price
$1082.83
$456.42 premium
Intrinsic value data unavailable for NVO.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.5%
Earnings expanding 22.9% YoY
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Areas to Watch
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.
Bull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.6x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
EQIX profiles as a value stock while NVO is a declining play — different risk/reward profiles.
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
EQIX is growing revenue faster at 8.1% — sustainability is the question.
EQIX generates stronger free cash flow (-292M), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 50/100), backed by strong 33.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
Compare with Other REIT - SPECIALTY Stocks
Want to dig deeper into these stocks?